Share Email Print
cover

Proceedings Paper

Tin (IV) Etiopurpurin Dichloride: An Alternative To DHE?
Author(s): Alan R. Morgan; Greta M. Garbo; Rick W. Keck; Steven H. Selman
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Etiopurpurin is a photosensitizer developed from etioporphyrin I, which we have shown to be useful in PDT. Incorporation of tin into the macrocycle gives a derivative which appears to be more effective both in vitro and in vivo studies on tumor cytotoxicity, than the parent purpurin. In vitro studies have shown not only that tin etiopurpurin dichloride (SnET2C12) is an efficient photosensitizer, but also that its action spectrum appears to be consistent with both the absorption and emission spectra. In vivo studies include a histological examination of tumors treated with SnET2C12 and PDT which suggests that disruption of the tumor vasculature plays an active role in tumor necrosis; a twelve day dose response study to determine effective dose; a thirty day study to determine tumor regrowth; a study of normal tissue response to PDT and a study to determine the optimum time for phototherapy after injection of the drug. For these studies, the FANFT induced urothelial tumor line was used, although we have recently initiated studies on the R3327 AT rat anaplastic adenocarcinoma, a tumor which appears to be more resistant to PDT.

Paper Details

Date Published: 19 February 1988
PDF: 8 pages
Proc. SPIE 0847, New Directions in Photodynamic Therapy, (19 February 1988); doi: 10.1117/12.942708
Show Author Affiliations
Alan R. Morgan, University of Toledo (United States)
Greta M. Garbo, University of Toledo (United States)
Rick W. Keck, Medical College of Ohio (United States)
Steven H. Selman, Medical College of Ohio (United States)


Published in SPIE Proceedings Vol. 0847:
New Directions in Photodynamic Therapy
Douglas C. Neckers, Editor(s)

© SPIE. Terms of Use
Back to Top